Small Molecules in Oncology
Springer Berlin (Verlag)
978-3-662-51925-7 (ISBN)
Imatinib Mesylate.- Erlotinib.- Axitinib (AG-013736).- Lapatinib.- Sorafenib.- Sunitinib.- Dasatinib.- Nilotinib.- Bosutinib.- Decitabine.- Azacytidine/Azacitidine.- Bortezomib.- Temsirolimus.- Danusertib.- Vismodegib.- Everolimus.- Vemurafenib.- Vandetanib.- Trametinib.- Dabrafenib.- Ponatinib.- Regorafenib.- Cabozantinib.- Revlimid.- Ibrutinib.- Qizartinib.- Ruxolitinib.- Carfilzomib.- Afitinib.
"The book is recommended for healthcare professionals, scientists, and students in medical and scientific fields. In 25 well-written chapters, experts in their fields of research describe in great detail 12 compounds currently in clinical use for the treatment of hematological malignancies, and 13 compounds applicable to specific mutation-containing malignancies or aimed at interfering with the microenvironment (such as angiogenesis). ... This book provides important practical information on a wide variety of novel small molecule-based treatment approaches." (George Somlo, Doody's Book Reviews, April, 2015)
Erscheinungsdatum | 29.08.2016 |
---|---|
Reihe/Serie | Recent Results in Cancer Research |
Zusatzinfo | XVI, 417 p. 46 illus., 26 illus. in color. |
Verlagsort | Berlin |
Sprache | englisch |
Maße | 155 x 235 mm |
Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Hämatologie |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
Schlagworte | Cancer Research • Haematology • Hematology • Medicine • Molecular mechanisms of cancer • Oncogenic protein kinase inhibitors • Oncology • targeted therapy • Treatment of malignant diseases |
ISBN-10 | 3-662-51925-9 / 3662519259 |
ISBN-13 | 978-3-662-51925-7 / 9783662519257 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich